Compounded Medications, Explained

What is a compounded medication?

Compounding is the preparation or alteration of a medication for an identified patient. A realistic example might be removing an inactive ingredient because of a documented allergy, preparing a dosage form an available approved product cannot provide for that patient, or responding to a drug shortage under applicable legal conditions. The reason should be specific to the patient and explained by the prescriber.

Compounding is not the same as ordinary manufacturing, and it is not automatically appropriate because a product is cheaper, easier to market, or available online. A familiar active-ingredient name does not make a compounded product an approved generic or prove that it will perform like a branded medicine. The formulation, source, concentration, sterility controls, container, storage, and instructions all matter.

Sources: FDA: Compounding and the FDA

What does ‘not FDA-approved’ mean?

FDA approval applies to a finished drug that the agency has reviewed for safety, effectiveness, quality, labeling, and manufacturing controls for specified uses. An approved generic must meet FDA requirements, including demonstrating sameness and bioequivalence as applicable. A compounded drug does not pass through that premarket approval process.

A state pharmacy license authorizes pharmacy practice under that jurisdiction; it does not approve each finished drug. Registration as a 503B outsourcing facility places the facility in a federal category with particular requirements; it does not approve its products. Accreditation is a private credential and does not replace licensure. A prescription confirms that a clinician ordered a product for a patient; it does not convert the product into an FDA-approved drug.

503A versus 503B

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act create different conditions under which compounded drugs may qualify for exemptions from certain federal requirements. Traditional 503A practice generally centers on identified individual patients and state oversight. A 503B outsourcing facility registers with FDA and may make larger batches under additional federal requirements.

Neither designation is a quality ranking that a consumer can use by itself, and neither means the finished compounded drug is FDA-approved. Verify what the facility is, which regulator oversees the activity, whether a patient-specific prescription is involved, and which exact entity will dispense or distribute the product.

Sources: FDA: 503A and 503B overview · FDA: Registered outsourcing facilities

When might compounding be considered?

A clinician may consider compounding when an identified patient has a medical need that cannot be met by an available FDA-approved drug. The analysis should start with the patient’s need and the available approved alternatives, not with a predetermined online product. The exact legal conditions also depend on the compounder, product, ingredients, and current circumstances.

Preference and convenience can be part of a care conversation, but price preference alone does not establish a medical need. If compounding is proposed, ask what available approved options were considered, why they do not meet the identified need, and what uncertainties or additional risks accompany the proposed compounded formulation.

Shortages and changing federal policy

Drug-shortage status can affect whether FDA applies certain statutory restrictions or temporary enforcement policies to compounding activity. These policies can change as supply stabilizes. FDA’s current GLP-1 policy page states that tirzepatide and semaglutide are not on the agency’s drug-shortage list and describes the end of specified enforcement-discretion periods in 2025.

In April 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them from bulk substances. Because proposals, litigation, shortages, and enforcement policies can change, consumers and professionals should check dated FDA information rather than relying on an old advertisement. Shortage status never makes a compounded drug FDA-approved, equivalent, or appropriate for every patient.

Sources: FDA: GLP-1 supply and compounding policy updates · FDA: 2026 proposed 503B bulks-list action

What are the principal risks?

Compounded medicines can fill legitimate patient needs, and the presence of risk does not mean every compounded product is defective. The concern is that FDA does not review each finished compounded drug before marketing. Potential problems include contamination, potency variation, incorrect concentration, measurement errors, unsuitable ingredient substitution, storage or shipping failures, confusing instructions, and fraudulent labeling.

For compounded GLP-1 products, FDA has warned about semaglutide salt forms, labels that name pharmacies that did not make the product, adverse events associated with dosing errors, and products sold directly to consumers as “research use” or “not for human consumption.” Those phrases are a warning, not a workaround. After purchase, ask your prescribing team through the clinical patient portal to resolve any mismatch in the package, label, concentration, or instructions before use. Email Skylar for help locating your portal access instructions.

Sources: FDA: Concerns with unapproved GLP-1 drugs · FDA: Compounded semaglutide dosing errors

Milligrams, milliliters, concentration, and syringe units

Milligrams measure the amount of medication. Milliliters measure liquid volume. A concentration such as mg/mL states how much medication is present in a given volume. Syringe units are markings that represent volume on a particular syringe; they are not a universal medication dose. The total amount in a vial and the vial’s intended duration are separate facts.

Because compounded vials may have different concentrations, the same number of syringe units can represent different medication amounts. FDA has linked confusion among milligrams, milliliters, and units to dosing errors, including errors requiring medical care. Never copy a friend’s, influencer’s, or previous vial’s unit instruction. Obtain written directions for the exact labeled vial and ask the prescribing clinician to clarify discrepancies. This table is educational and does not provide a calculation for self-dosing.

Sources: FDA: Measurement and concentration warning

How should someone verify a pharmacy?

Obtain the legal pharmacy name and physical location before payment or shipment. Check the active license with the state board of pharmacy where it is located and any license required in your state. If the company claims 503B status, check FDA’s registered-outsourcing-facility list separately. Accreditation can be additional information, but it does not replace active licensure, FDA registration where claimed, or product-specific questions.

Confirm that the label and package identify the same pharmacy, provide working contact information, and match what the prescriber ordered. Ask who handles clinical questions versus shipping or billing issues, how temperature excursions are managed, and how a suspected quality problem or adverse event can be reported. Keep photographs of the label and packaging and contact your prescribing team before using a product that arrives damaged, warm, frozen, leaking, or inconsistent with the prescription.

• Obtain the pharmacy’s legal name and physical location
• Verify state-board licensure
• Check FDA 503B registration separately when claimed
• Match the label, package, prescription, and pharmacy contact
• Confirm shipping, storage, and temperature-excursion instructions
• Know how to reach your clinical team through the patient portal and report a suspected problem

What should be disclosed before payment?

Before payment, a program should disclose possible treatment categories and realistic price ranges, membership or consultation fees, shipping and supply charges, refill timing, automatic renewal, cancellation terms, refund rules, and what happens if treatment is not approved or later changes. The program should not promise a prescription before a licensed clinician evaluates the patient.

After clinical review, the patient should receive the exact medication, formulation, concentration, dose, schedule, pharmacy, plan length, and follow-up recommendation that apply to them. Those details cannot be responsibly finalized by marketing copy before evaluation. Paying for an intake, membership, or plan does not guarantee approval, a particular drug, or a refund unless the written terms say so.

What should appear on the label?

Read the entire label before use. Depending on the product and applicable requirements, it should clearly identify the patient where applicable, active ingredient and formulation, concentration or strength, directions, route, storage conditions, beyond-use date, quantity, pharmacy identity, and contact information. The prescription, vial, outer package, and written instructions should agree.

A beyond-use date is not the same as an FDA-approved manufacturer expiration date. Do not use a product with an unclear ingredient, missing concentration, damaged seal, conflicting directions, unfamiliar pharmacy, or “research use only” language. Contact your prescribing team for a resolution rather than guessing.

Questions for the prescriber

The prescriber should explain the clinical decision, not only the checkout process.

• What patient-specific need is not met by an available approved product?
• Which approved alternatives were considered?
• What exact ingredient, formulation, route, and concentration are proposed?
• What adverse effects, contraindications, and interactions matter for me?
• How will benefit, tolerability, and safety be followed?
• What happens if the plan changes or treatment is not approved?

Questions about your dispensed medication

After purchase, send product-specific preparation, label, storage, and measurement questions to your prescribing team through the clinical patient portal. For delivery or access help, email Skylar at skylar@prettygirlspeptide.com.

• Did this pharmacy compound the product named on the label?
• What are the concentration, total vial amount, and intended duration?
• Which syringe or device matches the written directions?
• How should the product be stored and what is its beyond-use date?
• What should I do after a temperature excursion or damaged shipment?
• How do I report a suspected quality problem or medication error?